The
demand for protein therapeutics has increased considerably, owing to
increase in prevalence of chronic diseases and development of
plasma-derived therapies. In recent years, proteins expression
systems have gained significant traction for therapeutic applications
and the number of proteins launched or approved into clinical trials
has continually increased. According to the National Center for
Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug
Administration (FDA) approved more than 140 recombinant therapeutic
proteins for human use and several hundred are currently in
development.
However,
high cost associated with therapeutic proteins and stringent
government regulations towards approval of protein therapies are
expected to hinder market growth. For instance, in India, a vial of
Avastin (Bevacizumab mostly produced by the mammalian cell expression
system), a monoclonal antibody, cost between US$ 372.65 to US$
402.46. Moreover, immunogenicity is also a major concern for all
recombinant drugs, as all biotechnologically produced therapeutics
may exhibit some form of immunogenicity.
Get a Request Sample of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2383
However,
high cost associated with therapeutic proteins and stringent
government regulations towards approval of protein therapies are
expected to hinder market growth. For instance, in India, a vial of
Avastin (Bevacizumab mostly produced by the mammalian cell expression
system), a monoclonal antibody, cost between US$ 372.65 to US$
402.46. Moreover, immunogenicity is also a major concern for all
recombinant drugs, as all biotechnologically produced therapeutics
may exhibit some form of immunogenicity.
Currently,
most of all recombinant therapeutic proteins are produced in
mammalian cells, mammalian cells are capable of producing
high-quality proteins similar to the naturally occurring ones.
Furthermore, many approved recombinant therapeutic proteins are
generated in E. coli. (Bacteria) due to its well-characterized
genetics, rapid growth, and high-yield production.
Request
for Customization of Research Report:
https://www.coherentmarketinsights.com/insight/request-customization/2383
Pharmaceutical
companies are progressively focusing on research using proteins to
develop novel effective therapeutics. Advances in molecular control
of gene expression are also expanding the opportunities for protein
expression systems. The next generation expression systems are
gaining traction as drug manufacturers are looking for cheaper ways
to express new biologic drugs. For instance, on 6 December 2018,
AMSBIO introduced ALiCE, a new high-yield cell-free protein
expression system. ALiCE is a unique eukaryotic system, which yields
an unprecedented 3 mg/ml of protein in batch mode.
The
production of proteins in appropriate quantity and quality is an
essential requirement of the biopharmaceutical and biotechnology
industry. Therapeutic proteins provide important therapies for a
variety of diseases such as anemia, diabetes, cancer, infectious
diseases, and hemophilia. There is a growing demand for recombinant
proteins for therapeutic applications. Common therapeutic proteins
include antibodies, anticoagulants, hormones, FC fusion proteins,
interleukins, and enzymes. Human proteins obtained through genetic
engineering play a crucial role in therapeutic medicines.
Inquire about Discount on this Report @
https://www.coherentmarketinsights.com/insight/request-discount/2383
Key
players operating in the global protein expression systems market
include Agilent Technologies, Inc., Becton, Dickinson & Company,
Lonza Group Ltd., GenScript Biotech Corporation, Bio-Rad
Laboratories, Inc., Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific
Inc., Takara Bio Inc., Synthetic Genomics Inc., Lucigen Corporation,
Promega Corporation, ARTES Biotechnology GmbH, ProteoGenix, Addgene
Inc., Geneva Biotech, Profacgen, and Peak Proteins Ltd.
Coherent Market Insights is a prominent market
research and consulting firm offering action-ready syndicated
research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
Mr.
Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
No comments:
Post a Comment